In urban mainland China, physicians did show a preference for AC plus taxane regimens, over docetaxel plus cyclophosphamide, which are more commonly used in the US, whereas EC-based regimens are dominant among EU5 physicians for treating stage I HR+/HER2(−) breast cancer patients. Here, ERBB2 is linked to breast carcinoma.